Brokerages Set Immunocore Holdings plc (NASDAQ:IMCR) Price Target at $65.64

Shares of Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report) have earned an average recommendation of "Moderate Buy" from the thirteen brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $65.64.

Several research analysts have commented on IMCR shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Immunocore in a research note on Monday, September 9th. HC Wainwright reaffirmed a "buy" rating and set a $100.00 price target on shares of Immunocore in a research note on Thursday, October 24th. UBS Group initiated coverage on shares of Immunocore in a research report on Thursday, October 24th. They issued a "sell" rating and a $24.00 price objective on the stock. Guggenheim downgraded shares of Immunocore from a "buy" rating to a "neutral" rating in a research note on Monday, October 7th. Finally, Morgan Stanley reaffirmed an "equal weight" rating and set a $35.00 target price (down previously from $74.00) on shares of Immunocore in a research note on Friday, December 13th.

Immunocore Price Performance

Shares of Immunocore stock traded up $0.04 during trading hours on Friday, reaching $29.86. The company's stock had a trading volume of 81,212 shares, compared to its average volume of 223,656. The firm has a 50 day moving average price of $31.34 and a 200-day moving average price of $33.93. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The stock has a market cap of $1.49 billion, a P/E ratio of -31.43 and a beta of 0.73. Immunocore has a one year low of $27.69 and a one year high of $76.98.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.50. The company had revenue of $80.25 million for the quarter, compared to analysts' expectations of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The firm's revenue for the quarter was up 23.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.59) earnings per share. On average, analysts predict that Immunocore will post -0.94 EPS for the current year.

Institutional Trading of Immunocore

Institutional investors and hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP increased its position in Immunocore by 10.5% during the 3rd quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company's stock valued at $219,430,000 after purchasing an additional 668,382 shares during the period. FMR LLC boosted its stake in shares of Immunocore by 0.5% during the third quarter. FMR LLC now owns 4,836,040 shares of the company's stock valued at $150,546,000 after purchasing an additional 23,436 shares in the last quarter. Primecap Management Co. CA increased its holdings in Immunocore by 26.7% during the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company's stock valued at $76,954,000 after buying an additional 520,950 shares during the period. Bellevue Group AG raised its stake in Immunocore by 4.4% in the third quarter. Bellevue Group AG now owns 1,205,464 shares of the company's stock worth $37,526,000 after buying an additional 50,810 shares in the last quarter. Finally, Armistice Capital LLC lifted its holdings in Immunocore by 495.1% during the second quarter. Armistice Capital LLC now owns 976,000 shares of the company's stock worth $33,077,000 after buying an additional 812,000 shares during the period. 84.50% of the stock is currently owned by institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.